商品名：Yarvitan
Mitratapide is used to produce weight loss in dogs. It is related to another medication used for obesity in dogs, dirlotapide (Slentrol). Mitratapide is an inhibitor of the microsomal triglyceride transfer protein (MTP). Inhibition of this enzyme reduces the ability of intestinal enterocyces to process triglycerides. The accumulation of these triglycerides in the intestinal cells sends a signal to the central nervous system to suppress the appetite. In dogs the effect on the intestinal cells reduces the uptake of dietary lipids in association with decreased postprandial serum triglycerides, phospholipids, and cholesterol. The accumulation of triglycerides inside the enterocytes can be observed macroscopically and histopathologically. The weight loss is attributed to the reduced appetite, r
Mitratapide is used in the management of obesity in dogs. During the treatment protocol, there is a relatively moderate loss of weight, (6%-7% of the weight before treatment). It should not be used without instituting the proper protocol, as outlined by the sponsor. It should be used in an overall weight management program, which also includes appropriate dietary changes. Before using to treat overweight or obesity, rule out other diseases such as hypothyroidism or hyperadrenocorticism. At this time, it is approved in Europe, but it has not been approved in the US. It should not be used in cats.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
本系統僅確認已撤回之歷史犬用 Yarvitan 證據；未確認所在地目前有可取得且精確相符的產品，因此不得提供可執行劑量、處方或自動交互作用結論。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。